根据clinicaltrial.gov的临床试验注册结果,目前针对NF1患者MEK靶向治疗临床试验共有10项,其汇总如下 1.MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 2.Mitogen Activated Protein Kinase Kinase(MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People WithNeurofibromatosis Type 1...
A number of MEK inhibitors have progressed into clinical trials since the first MEK inhibitor (PD098059) was described in the literature in 1995 (Table1). Currently thirteen MEK inhibitors have been tested clinically but only trametinib (GSK1120212), a selective inhibitor of MEK 1 and 2, has ...
SUZHOU,China,Dec. 27, 2017/PRNewswire/ --CStone Pharmaceuticals (Suzhou) Co., Ltd, announced today that a formal application for clinical trial approval has been submitted to Human Research Ethics Committees of Linear Clinical Research Center inAustraliafor CS3006, a small-molecule inhibitor of mi...
Clinical trialMEKSelumetinibPembrolizumabSolid tumorsMEK inhibitors have immunomodulatory activity and potential for synergistic activity when combined with PD-1 inhibitors. We evaluated selumetinib (inhibitor of MEK1/2) plus pembrolizumab (antiPD-1 antibody) in patients with advanced/metastatic solid tumors...
Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenic BRAFV600 in melanoma1,2. We conducted S1320, a randomized, open-label, phase 2 clinical trial (NCT02196181) evaluating whether intermittent dosing of the BRAF inhibitor dabrafenib ...
NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol. 2021;39(7):797–806. 52. Moertel C: ReNeu: phase 2b trial of mirdametinib, a MEK1/2 ...
9. Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358–367 (2015).10. Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer....
Therefore, preclinical and clinical trials were initiated to investigate the potential for a MEK inhibitor to impede some of these resistance mechanisms, as MEK is a molecule downstream of BRAF in the pathway. With regard to toxicity, proliferative skin lesions are commonly seen in the setting of...
The mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor Selumetinib has been tested in clinical trials for various cancers. Moreover, Selumetinib has also been shown to inhibit the production of IL-6. In a retrospective analysis of a phase II clinical trial in ...
Therefore, it will be cru- cial to identify patient subpopulations most likely to benefit from MEK inhibitor therapy to minimize the risk:benefit ratio for patients. Conclusions Currently, more than a dozen inhibitors of MEK1 and MEK2 are in clinical development, including binimeti- nib. In ...